Prognostic significance of implantable defibrillator shock: Are all shocks created equal?

Journal of Cardiovascular Electrophysiology

Volumn 23, Issue 7, 2012, Pages 741-743

  Freedberg, Nahum A ^a   Feldman, Alexander ^a  

^a HAEMEK MEDICAL CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT;

CARDIAC RESYNCHRONIZATION THERAPY DEVICE; CARDIOGENIC SHOCK; CARDIOVASCULAR MORTALITY; CLINICAL STUDY; COMORBIDITY; DEFIBRILLATOR; DISEASE REGISTRY; EDITORIAL; ELECTROGRAPHY; FOLLOW UP; HEART ATRIUM ARRHYTHMIA; HEART ATRIUM FIBRILLATION; HEART DEATH; HEART FAILURE; HUMAN; MONOMORPHIC VENTRICULAR TACHYCARDIA; MORPHOLOGY; OBSERVATIONAL STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENT DISEASE; REVASCULARIZATION; SINUS TACHYCARDIA;

ATRIAL FIBRILLATION; DEATH, SUDDEN, CARDIAC; DEFIBRILLATORS, IMPLANTABLE; ELECTRIC COUNTERSHOCK; EQUIPMENT FAILURE; FEMALE; HEART FAILURE; HUMANS; MALE;

EID: 84863718727     PISSN: 10453873     EISSN: 15408167     Source Type: Journal    
DOI: 10.1111/j.1540-8167.2012.02299.x     Document Type: Editorial

References (41)

1. Hallstrom AP, McAnulty JH, Wilkoff BL, Follmann D, Raitt MH, Carlson MD, Gillis AM, Shih H-T, Powell JL, Duff H, Halperin BD,: The Antiarrhythmics versus Implantable Defibrillator Trial I. Patients at lower risk of arrhythmia recurrence: A subgroup in whom implantable defibrillators may not offer benefit. J Am Coll Cardiol 2001; 37: 1093-1099.
2. Koller MT, Schaer B, Wolbers M, Sticherling C, Bucher HC, Osswald S,: Death without prior appropriate implantable cardioverter-defibrillator therapy: A competing risk study. Circulation 2008; 117: 1918-1926.
3. Sweeney MO,: The contradiction of appropriate shocks in primary prevention ICDs: Increasing and decreasing the risk of death. Circulation 2010; 122: 2638-2641.
4. Tung R, Zimetbaum P, Josephson ME,: A critical appraisal of implantable cardioverter-defibrillator therapy for the prevention of sudden cardiac death. J Am Coll Cardiol 2008; 52: 1111-1121.
5. Dorian P, Hohnloser SH, Thorpe KE, Roberts RS, Kuck K-H, Gent M, Connolly SJ,: Mechanisms underlying the lack of effect of implantable cardioverter-defibrillator therapy on mortality in high-risk patients with recent myocardial infarction: Insights from the Defibrillation in Acute Myocardial Infarction Trial (DINAMIT). Circulation 2010; 122: 2645-2652.
6. Stevenson WG, John RM,: Ventricular arrhythmias in patients with implanted defibrillators. Circulation 2011; 124: e411-e414.
7. Epstein AE, DiMarco JP, Ellenbogen KA, Estes NAM III, Freedman RA, Gettes LS, Gillinov AM, Gregoratos G, Hammill SC, Hayes DL, Hlatky MA, Newby LK, Page RL, Schoenfeld MH, Silka MJ, Stevenson LW, Sweeney MO,: ACC/AHA/HRS 2008 Guidelines for device-based therapy of cardiac rhythm abnormalities: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the ACC/AHA/NASPE 2002 Guideline Update for Implantation of Cardiac Pacemakers and Antiarrhythmia Devices) Developed in collaboration with the American Association for Thoracic Surgery and Society of Thoracic Surgeons. J Am Coll Cardiol 2008; 51: e1-e62.
8. Theuns DAMJ, Schaer BA, Soliman OII, Altmann D, Sticherling C, Geleijnse ML, Osswald S, Jordaens L,: The prognosis of implantable defibrillator patients treated with cardiac resynchronization therapy: Comorbidity burden as predictor of mortality. Europace 2011; 13: 62-69.
9. Moss AJ, Greenberg H, Case RB, Zareba W, Hall WJ, Brown MW, Daubert JP, McNitt S, Andrews ML, Elkin AD, for the Multicenter Automatic Defibrillator Implantation Trial IIRG: Long-term clinical course of patients after termination of ventricular tachyarrhythmia by an implanted defibrillator. Circulation 2004; 110: 3760-3765.
10. Singh JP, Hall WJ, McNitt S, Wang H, Daubert JP, Zareba W, Ruskin JN, Moss AJ, and the M-III: Factors influencing appropriate firing of the implanted defibrillator for ventricular tachycardia/fibrillation: Findings from the Multicenter Automatic Defibrillator Implantation Trial II (MADIT-II). J Am Coll Cardiol 2005; 46: 1712-1720.
11. Poole JE, Johnson GW, Hellkamp AS, Anderson J, Callans DJ, Raitt MH, Reddy RK, Marchlinski FE, Yee R, Guarnieri T, Talajic M, Wilber DJ, Fishbein DP, Packer DL, Mark DB, Lee KL, Bardy GH,: Prognostic importance of defibrillator shocks in patients with heart failure. N Engl J Med 2008; 359: 1009-1017.
12. van Welsenes GH, van Rees JB, Borleffs CJW, Cannegieter SC, Bax JJ, van Erven L, Schalij MJ,: Long-term follow-up of primary and secondary prevention implantable cardioverter defibrillator patients. Europace 2011; 13: 389-394.
13. Sweeney MO, Sherfesee L, DeGroot PJ, Wathen MS, Wilkoff BL,: Differences in effects of electrical therapy type for ventricular arrhythmias on mortality in implantable cardioverter-defibrillator patients. Heart Rhythm 2010; 7: 353-360.
14. Larsen GK, Evans J, Lambert WE, Chen Y, Raitt MH,: Shocks burden and increased mortality in implantable cardioverter-defibrillator patients. Heart Rhythm 2011; 8: 1881-1886.
15. Wilkoff BL, Hess M, Young J, Abraham WT,: Differences in tachyarrhythmia detection and implantable cardioverter defibrillator therapy by primary or secondary prevention indication in cardiac resynchronization therapy patients. J Cardiovasc Electrophysiol 2004; 15: 1002-1009.
16. Yoshida K, Liu T-Y, Scott C, Hero A, Yokokawa M, Gupta S, Good E, Morady F, Bogun F,: The value of defibrillator electrograms for recognition of clinical ventricular tachycardias and for pace mapping of post-infarction ventricular tachycardia. J Am Coll Cardiol 2010; 56: 969-979.
17. Josephson ME, Horowitz LN, Farshidi A, Spielman SR, Michelson EL, Greenspan AM,: Recurrent sustained ventricular tachycardia: 4. Pleomorphism. Circulation 1979; 59: 459-468.
18. Della Bella P, Riva S, Fassini G, Giraldi F, Berti M, Klersy C, Trevisi N,: Incidence and significance of pleomorphism in patients with postmyocardial infarction ventricular tachycardia: Acute and long-term outcome of radiofrequency catheter ablation. Eur Heart J 2004; 25: 1127-1138.
19. Hadid C, Almendral J, Ortiz M, Schwab JO, Janko S, Mischke K, Arribas F, Wolpert C, Ricci R, Adragao P, Cobo E, Navarro X, Quesada A,: Incidence, determinants, and prognostic implications of true pleomorphism of ventricular tachycardia in patients with implantable cardioverter-defribillators: A substudy of the DATAS Trial. Circ Arrhythm Electrophysiol 2011; 4: 33-42.
20. Freedberg NA, Hill JN, Fogel RI, Prystowsky EN,: Recurrence of symptomatic ventricular arrhythmias in patients with implantable cardioverter defibrillator after the first device therapy: Implications for antiarrhythmic therapy and driving restrictions. J Am Coll Cardiol 2001; 37: 1910-1915.
21. Sweeney MO, Wathen MS, Volosin K, Abdalla I, DeGroot PJ, Otterness MF, Stark AJ,: Appropriate and inappropriate ventricular therapies, quality of life, and mortality among primary and secondary prevention implantable cardioverter defibrillator patients: Results from the pacing fast VT reduces shock therapies (PainFREE Rx II) trial. Circulation 2005; 111: 2898-2905.
22. van Rees JB, Borleffs CJW, de Bie MK, Stijnen T, van Erven L, Bax JJ, Schalij MJ,: Inappropriate implantable cardioverter-defibrillator shocks: Incidence, predictors, and impact on mortality. J Am Coll Cardiol 2011; 57: 556-562.
23. Germano JJ, Reynolds M, Essebag V, Josephson ME,: Frequency and causes of implantable cardioverter-defibrillator therapies: Is device therapy proarrhythmic? Am J Cardiol 2006; 97: 1255-1261.
24. Daubert JP, Zareba W, Cannom DS, McNitt S, Rosero SZ, Wang P, Schuger C, Steinberg JS, Higgins SL, Wilber DJ, Klein H, Andrews ML, Hall WJ, Moss AJ, for the MIII: Inappropriate implantable cardioverter-defibrillator shocks in MADIT II: Frequency, mechanisms, predictors, and survival impact. J Am Coll Cardiol 2008; 51: 1357-1365.
25. Blendea D, Blendea M, Banker J, McPherson CA,: Troponin T elevation after implanted defibrillator discharge predicts survival. Heart 2009; 95: 1153-1158.
26. Schluter T, Baum H, Plewan A, Neumeier D,: Effects of implantable cardioverter defibrillator implantation and shock application on biochemical markers of myocardial damage. Clin Chem 2001; 47: 459-463.
27. Tereshchenko LG, Faddis MN, Fetics BJ, Zelik KE, Efimov IR, Berger RD,: Transient local injury current in right ventricular electrogram after implantable cardioverter-defibrillator shock predicts heart failure progression. J Am Coll Cardiol 2009; 54: 822-828.
28. Kleemann T, Hochadel M, Strauss M, Skarlos A, Seidl K, Zahn R,: Comparison between atrial fibrillation-triggered implantable cardioverter-defibrillator (ICD) shocks and inappropriate shocks caused by lead failure: Different impact on prognosis in clinical practice. J Cardiovasc Electrophysiol 2012; DOI:.
29. Healey JS, Connolly SJ, Gold MR, Israel CW, Van Gelder IC, Capucci A, Lau CP, Fain E, Yang S, Bailleul C, Morillo CA, Carlson M, Themeles E, Kaufman ES, Hohnloser SH,: Subclinical atrial fibrillation and the risk of stroke. N Engl J Med 366: 120-129.
30. Benjamin EJ, Wolf PA, D'Agostino RB, Silbershatz H, Kannel WB, Levy D,: Impact of atrial fibrillation on the risk of death: The Framingham Heart study. Circulation 1998; 98: 946-952.
31. Wang TJ, Larson MG, Levy D, Vasan RS, Leip EP, Wolf PA, D'Agostino RB, Murabito JM, Kannel WB, Benjamin EJ,: Temporal relations of atrial fibrillation and congestive heart failure and their joint influence on mortality: The Framingham Heart Study. Circulation 2003; 107: 2920-2925.
32. Santini M, Gasparini M, Landolina M, Lunati M, Proclemer A, Padeletti L, Catanzariti D, Molon G, Botto GL, La Rocca L, Grammatico A, Boriani G, cardiological centers participating in the ClinicalService P: Device-detected atrial tachyarrhythmias predict adverse outcome in real-world patients with implantable biventricular defibrillators. J Am Coll Cardiol 2011; 57: 167-172.
33. Deneke T, Lawo T, Gerritse B, Lemke B, for the European GEMDI: Mortality of patients with implanted cardioverter/defibrillators in relation to episodes of atrial fibrillation. Europace 2004; 6: 151-158.
34. Bunch TJ, Day JD, Olshansky B, Stolen KQ, Mullin CM,: Newly detected atrial fibrillation in patients with an implantable cardioverter-defibrillator is a strong risk marker of increased mortality. Heart Rhythm 2009; 6: 2-8.
35. Leclercq JF, Leenhardt A, Coumel P, Slama R,: Efficacy of beta-blocking agents in reducing the number of shocks in patients implanted with first-generation automatic defibrillators. Eur Heart J 1992; 13: 1180-1184.
36. Triposkiadis F, Karayannis G, Giamouzis G, Skoularigis J, Louridas G, Butler J,: The sympathetic nervous system in heart failure: Physiology, pathophysiology, and clinical implications. J Am Coll Cardiol 2009; 54: 1747-1762.
37. Swerdlow CD, Gunderson BD, Ousdigian KT, Abeyratne A, Stadler RW, Gillberg JM, Patel AS, Ellenbogen KA,: Downloadable algorithm to reduce inappropriate shocks caused by fractures of implantable cardioverter- defibrillator leads. Circulation 2008; 118: 2122-2129.
38. Swerdlow CD,: Supraventricular tachycardia-ventricular tachycardia discrimination algorithms in implantable cardioverter defibrillators: State-of-the-art review. J Cardiovas Electrophysiol 2001; 12: 606-612.
39. Reddy VY, Reynolds MR, Neuzil P, Richardson AW, Taborsky M, Jongnarangsin K, Kralovec S, Sediva L, Ruskin JN, Josephson ME,: Prophylactic catheter ablation for the prevention of defibrillator therapy. N Engl J Med 2007; 357: 2657-2665.
40. Khan MN, Jais P, Cummings J, Di Biase L, Sanders P, Martin DO, Kautzner J, Hao S, Themistoclakis S, Fanelli R, Potenza D, Massaro R, Wazni O, Schweikert R, Saliba W, Wang P, Al-Ahmad A, Beheiry S, Santarelli P, Starling RC, Dello Russo A, Pelargonio G, Brachmann J, Schibgilla V, Bonso A, Casella M, Raviele A, Haissaguerre M, Natale A,: Pulmonary-vein isolation for atrial fibrillation in patients with heart failure. N Engl J Med 2008; 359: 1778-1785.
41. Gasparini M, Auricchio A, Regoli F, Fantoni C, Kawabata M, Galimberti P, Pini D, Ceriotti C, Gronda E, Klersy C, Fratini S, Klein HH,: Four-year efficacy of cardiac resynchronization therapy on exercise tolerance and disease progression: The importance of performing atrioventricular junction ablation in patients with atrial fibrillation. J Am Coll Cardiol 2006; 48: 734-743.